Mr. Alon Bloomenfeld is CEO and founder of Raziel Therapeutics. He served in management positions and as a board member for many public and private companies in healthcare, the high-tech industry. Prior to founding Raziel, Mr. Bloomenfeld served as the CFO of Collplant (NASDAQ: CLGN), Biomedix Incubator Ltd. (TASE:BMDX), and BrightCom Technologies. (acquired by NYSE-traded Flextronics). He also served as financial manager at Libit Signal Processing, which was acquired by Texas Instruments (NYSE:TXN). Mr. Bloomenfeld holds an MBA from Manchester University and a Bachelor of Arts in Accounting and Finance from Tel Aviv Management Colle
